# A Study in Healthy Men to Test How Well Different Doses of BI 1839100 Are Tolerated (1490-0001)

> **NCT05354453** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 104 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BI 1839100
- **DRUG:** Placebo
- **DRUG:** allyl isothiocyanate (AITC)

## Key facts

- **NCT ID:** NCT05354453
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-23
- **Primary completion:** 2023-06-14
- **Final completion:** 2023-06-14
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2023-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05354453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05354453, "A Study in Healthy Men to Test How Well Different Doses of BI 1839100 Are Tolerated (1490-0001)". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT05354453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*